GLP Watchdog

Good Life Meds vs Hers

Hers has an open FDA warning letter dated September 9, 2025. Good Life Meds has none. On compounded semaglutide injection, the standing prices are within $1 a month of each other: $199 at Good Life Meds and $199 at Hers.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Good Life Meds / Hers

Good Life Meds logo

Good Life Meds

7.6/10

Hers logo

Hers

6.8/10

FDA warning letters
None on record
Pharmacy
Lowest standing price
$199/moCompounded semaglutide injection
$199/moCompounded semaglutide injection
States
43 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked September 2026
Visit Good Life Meds
Visit Hers

Neither Good Life Meds nor Hers pays us. Links to them earn nothing. Scores: Good Life Meds 7.6, Hers 6.8. How we are paid

What the record shows

  1. 01

    Hers has an open FDA warning letter dated September 9, 2025. Good Life Meds has none.

  2. 02

    Good Life Meds names two pharmacies. Hers names three pharmacies.

  3. 03

    On compounded semaglutide injection, the standing prices are within $1 a month of each other: $199 at Good Life Meds and $199 at Hers.

  4. 04

    Only Hers lists a price for brand-name tirzepatide pen.

  5. 05

    Hers covers seven states Good Life Meds does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Good Life Meds

Hers

Compounded semaglutide injection

$199/mo

$2,388 a year

$199/mo

$2,388 a year

Brand-name tirzepatide pen
Not sold or not priced

$299/mo

medication only, membership extra; not compared

Price includes
Medication, clinician visits, shipping
Medication
Billed separately
Not stated
Clinician visits, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
Auto-renewing subscription at the chosen interval
None
Refunds
All prescription sales final; refunds generally not offered
No refund guaranteed once the pharmacy has processed an order
Early-exit fee
None stated
Not stated

Read off each seller’s own pages. Good Life Meds: October 17, 2026. Hers: September 28, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Good Life Meds

7.6/10
  • No FDA warning letter on record
  • Price includes clinician visits
Visit Good Life Meds

The case for Hers

6.8/10
  • Sells brand-name tirzepatide pen, which Good Life Meds does not price
  • Lists 50 states against 43
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
Visit Hers

Scores

Good Life Meds 7.6 · Hers 6.8 out of 10. Six weighted parts.

Value25%

5.0A
vs
B
3.0

Effectiveness25%

9.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

9.0A
vs
B
7.0

Accessibility10%

8.9A
vs
B
10.0

Support10%

7.0A
vs
B
3.0

The score is the same formula for every seller. Payment does not enter it. Method

Good Life Meds vs Hers: questions

Hers has an open FDA warning letter dated September 9, 2025. Good Life Meds has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Good Life Meds names two pharmacies. Hers names three pharmacies. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
Neither, by more than $1 a month. Good Life Meds charges $199 a month and Hers $199 a month.
Good Life Meds states you can cancel at any time; refunds: all prescription sales final; refunds generally not offered. Hers states you can cancel at any time; refunds: no refund guaranteed once the pharmacy has processed an order.
Neither Good Life Meds nor Hers pays us. Links to them earn nothing. Scores: Good Life Meds 7.6, Hers 6.8.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks